Clinical Trials
293 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
TRIDENT-1
Turning Point Therapeutics, Inc.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
SUNRISE
AdventHealth Translational Research Institute
OvAR-Y
Washington University School of Medicine
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
University of Florida
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
iCaRe2
University of Nebraska
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Collection of Blood From Patients With Cancer
National Institutes of Health Clinical Center (CC)
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
JIVAN
Aurigene Discovery Technologies Limited
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
LIBRETTO-001
Eli Lilly and Company
PSI-Immune
University of Pittsburgh
TraveraRTGx
Travera Inc
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Institutes of Health Clinical Center (CC)
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
ASAP
Avera McKennan Hospital & University Health Center
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
miR-CIPN#1
University Hospital, Clermont-Ferrand
Oncology Episode Payment Model in Hawaii
University of Pennsylvania
ONE TEAM
Duke University
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Zhejiang University
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Ulsan University Hospital